Replies to post #12856 on FDA Plays

[SC 388]

XNPT: 3 near-term catalysts
(1) Arbaclofen Placarbil (AP) in patients with gastroesophageal reflux disease (GERD): Preliminary top-line results of Phase 2b in the 1st Qtr. '11
(2) Horizant: FDA PDUFA Date = 4/6/11 (GlaxoSmithKline)
(3) Horizant: PMDA in Japan (Astellas)